On January 14, the Health Services Superintendence (HSS), through Resolution 37/2019, approved the Guide on breast cancer pathology treatment. It covers treatments across cancer types and the requirements for obtaining reimbursements in paying for antibody based medicines. Trastuzumab is among the drugs covered under the guidelines. The resolution has been in force since January 2, 2019.

The Guide recognizes the right of all breast cancer patients to be evaluated by multidisciplinary teams in order to identify appropriate treatment approaches. On this, a distinction is made between systemic therapies for operable and metastatic breast cancer.

A list of medications qualifying for refunds and the grounds for their use are also included in the guide. The medicines covered by it are those containing the following drugs: trastuzumab, trastuzumab emtansina, lapatinib, pertuzumab, and fulvestrant.

The Single Refund System (SRS) will provide financial support on the mentioned medicines, up to the maximum amounts outlined here. To request refunds, health providers must enter, on the website of the Superintendency, information on the pathology, their affiliate number and the benefits or medications in question, among other data. To access the full text of the refund requirements click here and here.